Search results for: 'vitro'

The change in reimbursement for diagnostic testing, pressure from PAMA, regulatory trends in Europe, demand for large-scale testing, shift to precision diagnostics, emerging companies, and evolving business models demand assessing portfolio, evaluating competitor strategies, and exploring opportunities for business growth. The competitive nature of...

14 Mar 2022  |  North America  |  Market Outlook

Next-generation Diagnostics Outlook, 2022

Recovery in Routine Testing and Focus on Personalized Diagnostics to Propel Growth

Infographics

×

In vitro diagnostics introduces new technologies, sequencing methods, novel software algorithms, and multi-omics approaches to realise the goal of personalized medicine. Next-generation diagnostics has been the backbone of COVID-19-related emergency diagnosis, with an estimated 25% to 30% of revenue during 2020 and early 2021 related to this testin...

In this research deliverable, Frost & Sullivan’s analyst team provides bold perspectives and predictions for the Middle East and North Africa (MENA) region’s life sciences industry in 2020. The markets covered include pharmaceuticals, biotechnology, and in-vitro diagnostics. The analysis captures the impact of trends that are expected to transpire ...

Femtech is an emerging term and, as is the case with most new concepts, is poorly understood. While some relate Femtech only with products unique to the female anatomy (including consumer products), others dismiss it as just another term for a group of existing solutions. Frost & Sullivan believes it is a unique space and a place for new growth opp...